Immunis News and Resources

Immunis, Inc., a clinical-stage biotechnology company focused on developing multi-active biologics for immune-related diseases, has raised $25 million in its Series A-1 financing round. This funding will be used to support two Phase 2 clinical trials for IMM01-STEM, a promising